Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Magnetic Resonance Imaging | 81 | 2024 | 3486 | 5.430 |
Why?
|
Contrast Media | 51 | 2023 | 1085 | 4.890 |
Why?
|
Prostatic Neoplasms | 36 | 2024 | 1751 | 3.650 |
Why?
|
Image Enhancement | 20 | 2021 | 566 | 2.000 |
Why?
|
Gadolinium DTPA | 16 | 2017 | 256 | 1.480 |
Why?
|
Algorithms | 12 | 2024 | 1919 | 1.380 |
Why?
|
Image Processing, Computer-Assisted | 15 | 2024 | 1259 | 1.310 |
Why?
|
Models, Theoretical | 9 | 2018 | 493 | 1.200 |
Why?
|
Image Interpretation, Computer-Assisted | 13 | 2019 | 697 | 1.100 |
Why?
|
Ultrasonic Therapy | 6 | 2012 | 38 | 1.020 |
Why?
|
Prostate | 11 | 2023 | 408 | 1.010 |
Why?
|
Signal-To-Noise Ratio | 4 | 2021 | 109 | 1.000 |
Why?
|
Mammary Glands, Animal | 8 | 2020 | 80 | 0.990 |
Why?
|
Diffusion Magnetic Resonance Imaging | 12 | 2023 | 300 | 0.990 |
Why?
|
Mammary Neoplasms, Experimental | 7 | 2015 | 127 | 0.910 |
Why?
|
Arteries | 4 | 2021 | 179 | 0.890 |
Why?
|
Ultrasonics | 7 | 2012 | 39 | 0.850 |
Why?
|
Computer Simulation | 11 | 2021 | 1103 | 0.840 |
Why?
|
Mammary Neoplasms, Animal | 4 | 2020 | 57 | 0.760 |
Why?
|
Breast Neoplasms | 18 | 2023 | 3020 | 0.740 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 5 | 2015 | 117 | 0.740 |
Why?
|
Reproducibility of Results | 22 | 2021 | 2782 | 0.710 |
Why?
|
Muscle, Skeletal | 7 | 2020 | 473 | 0.710 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2014 | 160 | 0.670 |
Why?
|
Breast | 8 | 2017 | 289 | 0.590 |
Why?
|
Models, Biological | 13 | 2015 | 1770 | 0.590 |
Why?
|
Phantoms, Imaging | 5 | 2015 | 466 | 0.570 |
Why?
|
Organometallic Compounds | 4 | 2021 | 140 | 0.570 |
Why?
|
Carcinoma in Situ | 2 | 2015 | 53 | 0.560 |
Why?
|
Sensitivity and Specificity | 16 | 2023 | 2019 | 0.520 |
Why?
|
Animals | 50 | 2023 | 27715 | 0.520 |
Why?
|
Rats | 18 | 2017 | 4061 | 0.520 |
Why?
|
Male | 45 | 2024 | 42967 | 0.490 |
Why?
|
Magnetic Resonance Angiography | 3 | 2020 | 275 | 0.470 |
Why?
|
Hyperthermia, Induced | 5 | 2012 | 73 | 0.430 |
Why?
|
Imaging, Three-Dimensional | 4 | 2020 | 602 | 0.420 |
Why?
|
Humans | 71 | 2024 | 90640 | 0.410 |
Why?
|
Neoplasms, Experimental | 2 | 2005 | 270 | 0.410 |
Why?
|
Biomimetic Materials | 1 | 2012 | 24 | 0.390 |
Why?
|
Neoplasm Transplantation | 6 | 2010 | 397 | 0.380 |
Why?
|
Abdominal Abscess | 1 | 2011 | 23 | 0.380 |
Why?
|
Tumor Hypoxia | 2 | 2022 | 36 | 0.380 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 46 | 0.370 |
Why?
|
Subtraction Technique | 3 | 2009 | 130 | 0.360 |
Why?
|
Mice | 27 | 2023 | 11949 | 0.350 |
Why?
|
Meglumine | 3 | 2021 | 38 | 0.350 |
Why?
|
Middle Aged | 34 | 2023 | 26347 | 0.330 |
Why?
|
Camellia sinensis | 1 | 2009 | 7 | 0.330 |
Why?
|
Angiogenesis Modulating Agents | 1 | 2009 | 4 | 0.330 |
Why?
|
Peripheral Arterial Disease | 2 | 2021 | 98 | 0.320 |
Why?
|
Fluorine | 2 | 2005 | 17 | 0.310 |
Why?
|
Computed Tomography Angiography | 2 | 2021 | 158 | 0.310 |
Why?
|
Neovascularization, Pathologic | 5 | 2015 | 354 | 0.310 |
Why?
|
Diet, High-Fat | 2 | 2020 | 123 | 0.300 |
Why?
|
Fourier Analysis | 5 | 2016 | 128 | 0.300 |
Why?
|
Female | 41 | 2023 | 46894 | 0.300 |
Why?
|
Plant Extracts | 1 | 2009 | 245 | 0.280 |
Why?
|
Carcinogenesis | 2 | 2020 | 216 | 0.270 |
Why?
|
Adipose Tissue | 2 | 2006 | 263 | 0.270 |
Why?
|
Laser Therapy | 2 | 2018 | 149 | 0.270 |
Why?
|
Triple Negative Breast Neoplasms | 2 | 2020 | 176 | 0.260 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2006 | 14 | 0.260 |
Why?
|
Fluorocarbons | 1 | 2005 | 72 | 0.250 |
Why?
|
Ultrasonography | 4 | 2014 | 722 | 0.250 |
Why?
|
Aged | 21 | 2023 | 19424 | 0.240 |
Why?
|
Pilot Projects | 10 | 2021 | 879 | 0.240 |
Why?
|
Echo-Planar Imaging | 5 | 2008 | 52 | 0.240 |
Why?
|
Misonidazole | 2 | 2022 | 17 | 0.240 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2002 | 315 | 0.240 |
Why?
|
Body Water | 3 | 2004 | 35 | 0.230 |
Why?
|
Prostatectomy | 6 | 2023 | 475 | 0.230 |
Why?
|
Gadolinium | 2 | 2018 | 104 | 0.230 |
Why?
|
Muscle Neoplasms | 1 | 2004 | 17 | 0.230 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 419 | 0.220 |
Why?
|
PTEN Phosphohydrolase | 3 | 2023 | 138 | 0.220 |
Why?
|
Myocardium | 1 | 2006 | 574 | 0.220 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 188 | 0.220 |
Why?
|
Thorax | 2 | 2000 | 77 | 0.210 |
Why?
|
Neoplasm Invasiveness | 5 | 2020 | 570 | 0.210 |
Why?
|
Mice, Transgenic | 7 | 2018 | 1583 | 0.210 |
Why?
|
Retrospective Studies | 11 | 2023 | 9330 | 0.200 |
Why?
|
Carbon Dioxide | 2 | 2002 | 205 | 0.200 |
Why?
|
Oxygen | 4 | 2021 | 747 | 0.200 |
Why?
|
Water | 4 | 2009 | 287 | 0.200 |
Why?
|
Feasibility Studies | 7 | 2020 | 791 | 0.190 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 105 | 0.190 |
Why?
|
Receptor, ErbB-2 | 1 | 2023 | 253 | 0.190 |
Why?
|
Neoplasms | 7 | 2020 | 3030 | 0.190 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2023 | 163 | 0.190 |
Why?
|
Adult | 20 | 2023 | 26953 | 0.180 |
Why?
|
Rats, Inbred F344 | 4 | 2005 | 154 | 0.180 |
Why?
|
Leg | 1 | 2021 | 140 | 0.170 |
Why?
|
Acoustics | 2 | 1997 | 52 | 0.170 |
Why?
|
Neoadjuvant Therapy | 1 | 2023 | 388 | 0.170 |
Why?
|
Neoplasm Grading | 4 | 2023 | 376 | 0.170 |
Why?
|
Blood-Brain Barrier | 2 | 2023 | 75 | 0.160 |
Why?
|
Lower Extremity | 1 | 2020 | 89 | 0.160 |
Why?
|
Arterial Occlusive Diseases | 1 | 2020 | 110 | 0.160 |
Why?
|
Electromagnetic Fields | 1 | 1999 | 26 | 0.160 |
Why?
|
Microvessels | 2 | 2009 | 69 | 0.160 |
Why?
|
Ischemia | 1 | 2021 | 254 | 0.160 |
Why?
|
Disease Models, Animal | 8 | 2020 | 2409 | 0.150 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2018 | 35 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 2705 | 0.150 |
Why?
|
Dietary Sugars | 1 | 2018 | 8 | 0.150 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 12 | 0.150 |
Why?
|
Brain Neoplasms | 2 | 2014 | 781 | 0.150 |
Why?
|
Diet, Fat-Restricted | 1 | 2018 | 30 | 0.150 |
Why?
|
Information Storage and Retrieval | 2 | 2010 | 121 | 0.150 |
Why?
|
Prostatic Hyperplasia | 1 | 2019 | 90 | 0.150 |
Why?
|
Prospective Studies | 6 | 2018 | 4348 | 0.150 |
Why?
|
Hindlimb | 3 | 2010 | 96 | 0.150 |
Why?
|
Androgen Antagonists | 3 | 2023 | 138 | 0.150 |
Why?
|
Pulse Wave Analysis | 1 | 2017 | 10 | 0.140 |
Why?
|
Feeding Behavior | 1 | 2020 | 330 | 0.140 |
Why?
|
Therapy, Computer-Assisted | 2 | 1995 | 17 | 0.140 |
Why?
|
Wrist | 1 | 2017 | 28 | 0.140 |
Why?
|
Fatty Acids | 1 | 2018 | 141 | 0.140 |
Why?
|
Oxides | 3 | 2002 | 43 | 0.140 |
Why?
|
Time Factors | 7 | 2012 | 5366 | 0.140 |
Why?
|
Dietary Fats | 1 | 2017 | 135 | 0.130 |
Why?
|
Iron | 3 | 2002 | 173 | 0.130 |
Why?
|
Immunohistochemistry | 4 | 2016 | 1806 | 0.130 |
Why?
|
Gastrointestinal Microbiome | 1 | 2023 | 526 | 0.130 |
Why?
|
Durapatite | 1 | 2015 | 33 | 0.130 |
Why?
|
Biopsy | 6 | 2019 | 1192 | 0.120 |
Why?
|
Diagnosis, Differential | 5 | 2019 | 1608 | 0.120 |
Why?
|
Observer Variation | 2 | 2021 | 615 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 1096 | 0.120 |
Why?
|
ROC Curve | 5 | 2018 | 781 | 0.120 |
Why?
|
Evaluation Studies as Topic | 3 | 2006 | 270 | 0.120 |
Why?
|
Metal Nanoparticles | 1 | 2014 | 31 | 0.120 |
Why?
|
Calcium Oxalate | 1 | 2015 | 186 | 0.110 |
Why?
|
Kinetics | 5 | 2023 | 1550 | 0.110 |
Why?
|
Gold | 1 | 2014 | 42 | 0.110 |
Why?
|
Temperature | 4 | 1999 | 414 | 0.110 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2014 | 111 | 0.110 |
Why?
|
Reference Values | 2 | 2015 | 662 | 0.110 |
Why?
|
Crohn Disease | 2 | 2011 | 765 | 0.110 |
Why?
|
Doxorubicin | 1 | 2014 | 294 | 0.110 |
Why?
|
Oncolytic Virotherapy | 1 | 2013 | 42 | 0.110 |
Why?
|
Thermometers | 3 | 1999 | 6 | 0.110 |
Why?
|
Brain | 2 | 2003 | 2328 | 0.110 |
Why?
|
Models, Anatomic | 2 | 1998 | 92 | 0.110 |
Why?
|
Manganese Compounds | 1 | 2012 | 5 | 0.100 |
Why?
|
Neural Stem Cells | 1 | 2013 | 59 | 0.100 |
Why?
|
Cell Line, Tumor | 4 | 2023 | 2609 | 0.100 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2013 | 80 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 269 | 0.100 |
Why?
|
Disease Progression | 2 | 2014 | 1486 | 0.100 |
Why?
|
Metabolic Clearance Rate | 4 | 2015 | 120 | 0.100 |
Why?
|
Transducers | 3 | 1997 | 42 | 0.100 |
Why?
|
Niacinamide | 1 | 2012 | 100 | 0.100 |
Why?
|
Tumor Cells, Cultured | 3 | 2004 | 1049 | 0.100 |
Why?
|
Chlorides | 1 | 2012 | 104 | 0.100 |
Why?
|
Phenylurea Compounds | 1 | 2012 | 95 | 0.100 |
Why?
|
Stem Cell Transplantation | 1 | 2013 | 190 | 0.100 |
Why?
|
Scattering, Radiation | 1 | 1992 | 117 | 0.100 |
Why?
|
Glioma | 1 | 2014 | 295 | 0.100 |
Why?
|
Proteomics | 2 | 2023 | 242 | 0.090 |
Why?
|
Lymph Nodes | 1 | 2015 | 553 | 0.090 |
Why?
|
Tissue Culture Techniques | 1 | 2011 | 83 | 0.090 |
Why?
|
Ascites | 1 | 2011 | 56 | 0.090 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 280 | 0.090 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 303 | 0.090 |
Why?
|
Biopsy, Needle | 1 | 2011 | 233 | 0.090 |
Why?
|
Glioblastoma | 1 | 2013 | 267 | 0.090 |
Why?
|
Blood Vessels | 1 | 2011 | 94 | 0.090 |
Why?
|
Diffusion | 3 | 2013 | 94 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 726 | 0.090 |
Why?
|
X-Ray Microtomography | 1 | 2011 | 93 | 0.090 |
Why?
|
Swine | 1 | 2012 | 593 | 0.090 |
Why?
|
Mice, Knockout | 1 | 2015 | 2042 | 0.090 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 295 | 0.090 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 476 | 0.090 |
Why?
|
Injections | 3 | 2017 | 116 | 0.090 |
Why?
|
Macrophages | 2 | 2023 | 585 | 0.080 |
Why?
|
Glucose | 1 | 2012 | 635 | 0.080 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 340 | 0.080 |
Why?
|
Electron Spin Resonance Spectroscopy | 2 | 2022 | 321 | 0.080 |
Why?
|
Radiation Dosage | 2 | 2021 | 231 | 0.080 |
Why?
|
Extracellular Space | 1 | 2009 | 92 | 0.080 |
Why?
|
Endocrine Gland Neoplasms | 1 | 2009 | 6 | 0.080 |
Why?
|
Intestine, Small | 1 | 2011 | 299 | 0.080 |
Why?
|
Perfusion Imaging | 1 | 2009 | 50 | 0.080 |
Why?
|
Radiotherapy, Conformal | 1 | 2009 | 82 | 0.080 |
Why?
|
Aged, 80 and over | 4 | 2017 | 6816 | 0.080 |
Why?
|
Breast Diseases | 2 | 2011 | 101 | 0.080 |
Why?
|
Insulin-Secreting Cells | 1 | 2012 | 428 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 589 | 0.070 |
Why?
|
Artifacts | 2 | 2015 | 246 | 0.070 |
Why?
|
Leiomyoma | 1 | 2012 | 204 | 0.070 |
Why?
|
Mice, Nude | 4 | 2013 | 819 | 0.070 |
Why?
|
Signal Processing, Computer-Assisted | 2 | 2006 | 202 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2012 | 252 | 0.070 |
Why?
|
Tumor Burden | 2 | 2020 | 316 | 0.070 |
Why?
|
Ferrosoferric Oxide | 3 | 2002 | 19 | 0.070 |
Why?
|
Magnetite Nanoparticles | 3 | 2002 | 27 | 0.070 |
Why?
|
Dextrans | 3 | 2002 | 79 | 0.070 |
Why?
|
Equipment Design | 2 | 2006 | 423 | 0.070 |
Why?
|
Colitis | 1 | 2010 | 249 | 0.070 |
Why?
|
Protons | 2 | 2008 | 101 | 0.070 |
Why?
|
Genetic Therapy | 1 | 2009 | 373 | 0.070 |
Why?
|
Materials Testing | 1 | 2006 | 93 | 0.070 |
Why?
|
Hypoxia | 2 | 2022 | 660 | 0.070 |
Why?
|
Emulsions | 1 | 2005 | 19 | 0.060 |
Why?
|
Hot Temperature | 2 | 2014 | 207 | 0.060 |
Why?
|
Necrosis | 2 | 1996 | 211 | 0.060 |
Why?
|
Carcinoma | 1 | 2008 | 438 | 0.060 |
Why?
|
Area Under Curve | 3 | 2011 | 338 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 974 | 0.060 |
Why?
|
Spin Labels | 2 | 2015 | 107 | 0.060 |
Why?
|
Biophysical Phenomena | 2 | 1995 | 124 | 0.060 |
Why?
|
Biophysics | 2 | 1995 | 153 | 0.060 |
Why?
|
Lactates | 1 | 2023 | 36 | 0.060 |
Why?
|
Molecular Weight | 1 | 2004 | 332 | 0.060 |
Why?
|
Lead | 1 | 2023 | 28 | 0.060 |
Why?
|
Phagocytosis | 1 | 2023 | 86 | 0.050 |
Why?
|
General Surgery | 2 | 1996 | 244 | 0.050 |
Why?
|
Aging | 1 | 2008 | 730 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 98 | 0.050 |
Why?
|
Lactic Acid | 1 | 2023 | 95 | 0.050 |
Why?
|
Radiography | 3 | 2012 | 809 | 0.050 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2009 | 599 | 0.050 |
Why?
|
Antigens, Polyomavirus Transforming | 2 | 2015 | 47 | 0.050 |
Why?
|
Brain Chemistry | 1 | 2002 | 122 | 0.050 |
Why?
|
Wnt Signaling Pathway | 1 | 2023 | 103 | 0.050 |
Why?
|
Models, Statistical | 3 | 2011 | 576 | 0.050 |
Why?
|
Motion | 1 | 2022 | 98 | 0.050 |
Why?
|
Rhabdomyosarcoma | 1 | 2002 | 43 | 0.050 |
Why?
|
beta Catenin | 1 | 2023 | 267 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2023 | 385 | 0.050 |
Why?
|
Cell Hypoxia | 1 | 2022 | 173 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 342 | 0.050 |
Why?
|
Pregnancy | 2 | 2023 | 3070 | 0.050 |
Why?
|
Lipopolysaccharides | 1 | 2023 | 295 | 0.050 |
Why?
|
Tibial Arteries | 1 | 2021 | 5 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2009 | 1549 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2023 | 8379 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2022 | 198 | 0.050 |
Why?
|
Fibula | 1 | 2021 | 32 | 0.050 |
Why?
|
Mice, Inbred C3H | 1 | 2020 | 371 | 0.040 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2021 | 99 | 0.040 |
Why?
|
Regional Blood Flow | 1 | 2020 | 198 | 0.040 |
Why?
|
Young Adult | 3 | 2017 | 6426 | 0.040 |
Why?
|
Indicator Dilution Techniques | 1 | 2019 | 9 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 375 | 0.040 |
Why?
|
Cytological Techniques | 1 | 1999 | 32 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 1935 | 0.040 |
Why?
|
Microwaves | 1 | 1999 | 36 | 0.040 |
Why?
|
Blood Flow Velocity | 1 | 1999 | 199 | 0.040 |
Why?
|
Ultrasonography, Interventional | 1 | 1999 | 126 | 0.040 |
Why?
|
Fructose | 1 | 2018 | 36 | 0.040 |
Why?
|
Image-Guided Biopsy | 1 | 2018 | 78 | 0.040 |
Why?
|
Weaning | 1 | 2017 | 25 | 0.040 |
Why?
|
Random Allocation | 1 | 2018 | 327 | 0.040 |
Why?
|
Radial Artery | 1 | 2017 | 33 | 0.040 |
Why?
|
Neoplasm, Residual | 1 | 2018 | 185 | 0.030 |
Why?
|
Adiposity | 1 | 2017 | 76 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2001 | 1066 | 0.030 |
Why?
|
Pressure | 1 | 2017 | 167 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2023 | 2502 | 0.030 |
Why?
|
Time | 1 | 2016 | 77 | 0.030 |
Why?
|
Thermal Conductivity | 1 | 1996 | 3 | 0.030 |
Why?
|
Sonication | 1 | 1996 | 4 | 0.030 |
Why?
|
Auditory Perception | 1 | 1997 | 97 | 0.030 |
Why?
|
Mathematics | 1 | 1996 | 191 | 0.030 |
Why?
|
Simian virus 40 | 1 | 2015 | 35 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2008 | 2370 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2002 | 1182 | 0.030 |
Why?
|
Edema | 1 | 2014 | 71 | 0.030 |
Why?
|
Color | 1 | 2014 | 85 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2014 | 124 | 0.030 |
Why?
|
Mammography | 1 | 2017 | 468 | 0.030 |
Why?
|
Cells, Cultured | 1 | 1999 | 2895 | 0.030 |
Why?
|
Rabbits | 1 | 2014 | 641 | 0.030 |
Why?
|
Perfusion | 1 | 2014 | 255 | 0.030 |
Why?
|
Streptozocin | 1 | 2012 | 55 | 0.030 |
Why?
|
Signal Transduction | 1 | 2023 | 3431 | 0.030 |
Why?
|
Adenoviridae | 1 | 2013 | 349 | 0.020 |
Why?
|
Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2012 | 101 | 0.020 |
Why?
|
Postoperative Period | 1 | 2012 | 301 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 491 | 0.020 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2012 | 191 | 0.020 |
Why?
|
Risk Assessment | 1 | 2019 | 2338 | 0.020 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 46 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2012 | 368 | 0.020 |
Why?
|
Fluorescence | 1 | 2011 | 104 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2011 | 238 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 1242 | 0.020 |
Why?
|
Intestines | 1 | 2013 | 416 | 0.020 |
Why?
|
Ileum | 1 | 2011 | 168 | 0.020 |
Why?
|
Angiography | 1 | 2011 | 208 | 0.020 |
Why?
|
Extremities | 1 | 2011 | 176 | 0.020 |
Why?
|
Biological Transport | 1 | 2010 | 403 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2015 | 2019 | 0.020 |
Why?
|
Regression Analysis | 1 | 2010 | 591 | 0.020 |
Why?
|
Deuterium | 1 | 2008 | 33 | 0.020 |
Why?
|
Spectrophotometry | 1 | 2008 | 108 | 0.020 |
Why?
|
Microscopy | 1 | 2008 | 89 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 441 | 0.020 |
Why?
|
Dogs | 2 | 1999 | 704 | 0.020 |
Why?
|
Endoscopy | 1 | 2011 | 353 | 0.020 |
Why?
|
Radiology | 1 | 2008 | 204 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2009 | 1709 | 0.020 |
Why?
|
Inflammation | 1 | 2011 | 990 | 0.020 |
Why?
|
Kidney | 2 | 1999 | 1150 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2010 | 3278 | 0.010 |
Why?
|
Prognosis | 1 | 2009 | 3813 | 0.010 |
Why?
|
Ribs | 1 | 1999 | 46 | 0.010 |
Why?
|
Lung | 1 | 1999 | 1305 | 0.010 |
Why?
|